| Year |
Citation |
Score |
| 2021 |
Hirschhorn D, Betof Warner A, Maniyar R, Chow A, Mangarin LM, Cohen AD, Hamadene L, Rizzuto GA, Budhu S, Suek N, Liu C, Houghton AN, Merghoub T, Wolchok JD. Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. Jci Insight. 6. PMID 34676831 DOI: 10.1172/jci.insight.151035 |
0.75 |
|
| 2017 |
Budhu S, Schaer DA, Li Y, Toledo-Crow R, Panageas K, Yang X, Zhong H, Houghton AN, Silverstein SC, Merghoub T, Wolchok JD. Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Science Signaling. 10. PMID 28851824 DOI: 10.1126/Scisignal.Aak9702 |
0.552 |
|
| 2014 |
Budhu S, Schaer D, Li Y, Houghton A, Silverstein S, Merghoub T, Wolchok JD. Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P192 |
0.55 |
|
| 2013 |
Yuan J, Ku GY, Adamow M, Mu Z, Tandon S, Hannaman D, Chapman P, Schwartz G, Carvajal R, Panageas KS, Houghton AN, Wolchok JD. Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. Journal For Immunotherapy of Cancer. 1: 20. PMID 24829756 DOI: 10.1186/2051-1426-1-20 |
0.435 |
|
| 2013 |
Schaer DA, Budhu S, Liu C, Bryson C, Malandro N, Cohen A, Zhong H, Yang X, Houghton AN, Merghoub T, Wolchok JD. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunology Research. 1: 320-31. PMID 24416730 DOI: 10.1158/2326-6066.Cir-13-0086 |
0.543 |
|
| 2013 |
Diab A, Jenq RR, Rizzuto GA, Cohen AD, Huggins DW, Merghoub T, Engelhorn ME, Guevara-Patiño JA, Suh D, Hubbard-Lucey VM, Kochman AA, Chen S, Zhong H, Wolchok JD, van den Brink MR, ... Houghton AN, et al. Enhanced responses to tumor immunization following total body irradiation are time-dependent. Plos One. 8: e82496. PMID 24349298 DOI: 10.1371/Journal.Pone.0082496 |
0.789 |
|
| 2013 |
Rajaram M, Zhang J, Wang T, Li J, Kuscu C, Qi H, Kato M, Grubor V, Weil RJ, Helland A, Borrenson-Dale AL, Cho KR, Levine DA, Houghton AN, Wolchok JD, et al. Two Distinct Categories of Focal Deletions in Cancer Genomes. Plos One. 8: e66264. PMID 23805207 DOI: 10.1371/Journal.Pone.0066264 |
0.384 |
|
| 2013 |
Budhu S, Schaer D, Li Y, Houghton A, Silverstein S, Merghoub T, Wolchok J. Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment Journal For Immunotherapy of Cancer. 1: P173. DOI: 10.1186/2051-1426-1-S1-P173 |
0.558 |
|
| 2013 |
Moskalenko M, Pan M, Hashimoto D, Mortha A, Bernardo SG, Leboeuf M, Houghton A, Wolchok J, Burakoff S, Merad M, Saenger YM. Abstract A43: Therapeutic efficacy of antitumor monoclonal antibodies combined with chemotherapy depends on innate immunity and NK1.1- innate lymphoid cells. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-A43 |
0.53 |
|
| 2012 |
Hirschhorn-Cymerman D, Budhu S, Kitano S, Liu C, Zhao F, Zhong H, Lesokhin AM, Avogadri-Connors F, Yuan J, Li Y, Houghton AN, Merghoub T, Wolchok JD. Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. The Journal of Experimental Medicine. 209: 2113-26. PMID 23008334 DOI: 10.1084/Jem.20120532 |
0.556 |
|
| 2012 |
Cao H, Dai P, Wang W, Li H, Yuan J, Wang F, Fang CM, Pitha PM, Liu J, Condit RC, McFadden G, Merghoub T, Houghton AN, Young JW, Shuman S, et al. Innate immune response of human plasmacytoid dendritic cells to poxvirus infection is subverted by vaccinia E3 via its Z-DNA/RNA binding domain. Plos One. 7: e36823. PMID 22606294 DOI: 10.1371/Journal.Pone.0036823 |
0.326 |
|
| 2012 |
Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, Rizzuto GA, Lazarus JJ, Pamer EG, Houghton AN, Merghoub T, Wolchok JD. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Research. 72: 876-86. PMID 22174368 DOI: 10.1182/Blood.V118.21.2171.2171 |
0.771 |
|
| 2012 |
Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, Gallardo H, Liu C, Merghoub T, Hefter B, Dolgalev I, Viale A, Heguy A, De Stanchina E, Cobrinik D, ... ... Houghton A, et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene. 31: 446-57. PMID 21725359 DOI: 10.1038/Onc.2011.250 |
0.374 |
|
| 2011 |
Dai P, Cao H, Merghoub T, Avogadri F, Wang W, Parikh T, Fang CM, Pitha PM, Fitzgerald KA, Rahman MM, McFadden G, Hu X, Houghton AN, Shuman S, Deng L. Myxoma virus induces type I interferon production in murine plasmacytoid dendritic cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-dependent pathway. Journal of Virology. 85: 10814-25. PMID 21835795 DOI: 10.1128/Jvi.00104-11 |
0.341 |
|
| 2011 |
Schaer DA, Li Y, Merghoub T, Rizzuto GA, Shemesh A, Cohen AD, Li Y, Avogadri F, Toledo-Crow R, Houghton AN, Wolchok JD. Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope. Plos One. 6: e21214. PMID 21731676 DOI: 10.1371/Journal.Pone.0021214 |
0.768 |
|
| 2011 |
Orlandi F, Guevara-Patiño JA, Merghoub T, Wolchok JD, Houghton AN, Gregor PD. Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice. Vaccine. 29: 3646-54. PMID 21435405 DOI: 10.1016/J.Vaccine.2011.03.017 |
0.409 |
|
| 2011 |
Romano E, Rossi M, Ratzinger G, de Cos MA, Chung DJ, Panageas KS, Wolchok JD, Wolchock JD, Houghton AN, Chapman PB, Heller G, Yuan J, Young JW. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1984-97. PMID 21355077 DOI: 10.1158/1078-0432.Ccr-10-3421 |
0.438 |
|
| 2011 |
Saenger YM, Pan M, Hashimoto D, Glodny B, Shah S, Houghton AN, Merghoub T, Wolchok JD, Merad M. Abstract 4742: Anti-tyrosinase related protein 1 (TRP1) antibody combined with cyclophosphamide induces adaptive immunity against melanoma Cancer Research. 71: 4742-4742. DOI: 10.1158/1538-7445.Am2011-4742 |
0.571 |
|
| 2010 |
Avogadri F, Merghoub T, Maughan MF, Hirschhorn-Cymerman D, Morris J, Ritter E, Olmsted R, Houghton AN, Wolchok JD. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. Plos One. 5. PMID 20844763 DOI: 10.1371/Journal.Pone.0012670 |
0.554 |
|
| 2010 |
Ginsberg BA, Gallardo HF, Rasalan TS, Adamow M, Mu Z, Tandon S, Bewkes BB, Roman RA, Chapman PB, Schwartz GK, Carvajal RD, Panageas KS, Terzulli SL, Houghton AN, Yuan JD, et al. Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4057-65. PMID 20647477 DOI: 10.1158/1078-0432.Ccr-10-1093 |
0.4 |
|
| 2010 |
Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim SC, Diab A, Rizzuto G, Duan F, Perales MA, Merghoub T, Houghton AN, Wolchok JD. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. Plos One. 5: e10436. PMID 20454651 DOI: 10.1371/Journal.Pone.0010436 |
0.813 |
|
| 2010 |
Nakahara T, Uchi H, Lesokhin AM, Avogadri F, Rizzuto GA, Hirschhorn-Cymerman D, Panageas KS, Merghoub T, Wolchok JD, Houghton AN. Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood. 115: 4384-92. PMID 20154220 DOI: 10.1182/Blood-2009-11-251231 |
0.728 |
|
| 2010 |
Xing F, Persaud Y, Pratilas C, Janakiraman M, She Q, Liu C, Dolgalev I, Heguy A, Wolchok J, Cobrinik D, Houghton A, Taylor B, Rosen N, Solit D. Abstract 1971: Concurrent loss of PTEN and RB is sufficient to confer BRAF independence in melanomas harboring V600E BRAF mutations Cancer Research. 70: 1971-1971. DOI: 10.1158/1538-7445.Am10-1971 |
0.318 |
|
| 2009 |
Lin Y, Gallardo HF, Ku GY, Li H, Manukian G, Rasalan TS, Xu Y, Terzulli SL, Old LJ, Allison JP, Houghton AN, Wolchok JD, Yuan J. Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy. 11: 912-22. PMID 19903103 DOI: 10.3109/14653240903136987 |
0.501 |
|
| 2009 |
Ruby CE, Yates MA, Hirschhorn-Cymerman D, Chlebeck P, Wolchok JD, Houghton AN, Offner H, Weinberg AD. Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. Journal of Immunology (Baltimore, Md. : 1950). 183: 4853-7. PMID 19786544 DOI: 10.4049/Jimmunol.0901112 |
0.459 |
|
| 2009 |
Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, Xu Y, Li H, Vyas S, Mu Z, Chapman PB, Krown SE, Panageas K, Terzulli SL, Old LJ, ... Houghton AN, et al. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immunity. 9: 5. PMID 19496531 |
0.334 |
|
| 2009 |
Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, Cohen AD, Avogadri F, Lesokhin AM, Weinberg AD, Wolchok JD, Houghton AN. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. The Journal of Experimental Medicine. 206: 1103-16. PMID 19414558 DOI: 10.1084/Jem.20082205 |
0.759 |
|
| 2009 |
Duan F, Lin Y, Liu C, Engelhorn ME, Cohen AD, Curran M, Sakaguchi S, Merghoub T, Terzulli S, Wolchok JD, Houghton AN. Immune rejection of mouse tumors expressing mutated self. Cancer Research. 69: 3545-53. PMID 19351857 DOI: 10.1158/0008-5472.Can-08-2779 |
0.741 |
|
| 2009 |
Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, Zhong H, Panageas KS, Perales MA, Altan-Bonnet G, Wolchok JD, Houghton AN. Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. The Journal of Experimental Medicine. 206: 849-66. PMID 19332877 DOI: 10.1084/Jem.20081382 |
0.791 |
|
| 2009 |
Posnett DN, Engelhorn ME, Lin Y, Merghoub T, Duan F, Wolchok JD, Houghton AN. Development of effective vaccines for old mice in a tumor model. Vaccine. 27: 1093-100. PMID 19103244 DOI: 10.1016/J.Vaccine.2008.11.112 |
0.667 |
|
| 2009 |
Jenq RR, King CG, Volk C, Suh D, Smith OM, Rao UK, Yim NL, Holland AM, Lu SX, Zakrzewski JL, Goldberg GL, Diab A, Alpdogan O, Penack O, Na IK, ... ... Houghton AN, et al. Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation. Blood. 113: 1574-80. PMID 19011222 DOI: 10.1182/Blood-2008-05-155697 |
0.522 |
|
| 2009 |
Xing F, Persaud Y, Pratilas C, Janakiraman M, She Q, Liu C, Dolgalev I, Heguy A, Wolchok J, Cobrinik D, Houghton A, Taylor B, Rosen N, Solit D. Abstract B87: Genomic complexity and BRAF/MEK‐dependence in V600E BRAF mutant melanoma Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B87 |
0.333 |
|
| 2009 |
Lu SX, Na I-, Goldberg GL, Ghosh A, Hirschhorn-Cymerman D, King CG, Smith OM, Suh D, Rao U, Yim N, Holland AM, Penack O, Jenq RR, Teisch L, Meykler S, ... ... Houghton AN, et al. The T Cell Cytolytic Molecules Fas Ligand And Trail, The Trafficking Molecules CCR9, β7 Integrin And PSGL1, And The Immune Modulating Molecules OX40 And Ceacam1 Are Required For Thymic Graft-Versus-Host Disease Biology of Blood and Marrow Transplantation. 15: 123. DOI: 10.1016/J.Bbmt.2008.12.379 |
0.345 |
|
| 2008 |
Saenger YM, Li Y, Chiou KC, Chan B, Rizzuto G, Terzulli SL, Merghoub T, Houghton AN, Wolchok JD. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer Research. 68: 9884-91. PMID 19047169 DOI: 10.1158/0008-5472.Can-08-2233 |
0.778 |
|
| 2008 |
Cassard L, Cohen-Solal JF, Fournier EM, Camilleri-Broët S, Spatz A, Chouaïb S, Badoual C, Varin A, Fisson S, Duvillard P, Boix C, Loncar SM, Sastre-Garau X, Houghton AN, Avril MF, et al. Selective expression of inhibitory Fcgamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response. International Journal of Cancer. 123: 2832-9. PMID 18798552 DOI: 10.1002/Ijc.23870 |
0.535 |
|
| 2008 |
Perales MA, Yuan J, Powel S, Gallardo HF, Rasalan TS, Gonzalez C, Manukian G, Wang J, Zhang Y, Chapman PB, Krown SE, Livingston PO, Ejadi S, Panageas KS, Engelhorn ME, ... ... Houghton AN, et al. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 2022-9. PMID 18797450 DOI: 10.1038/Mt.2008.196 |
0.454 |
|
| 2008 |
Deng L, Dai P, Parikh T, Cao H, Bhoj V, Sun Q, Chen Z, Merghoub T, Houghton A, Shuman S. Vaccinia virus subverts a mitochondrial antiviral signaling protein-dependent innate immune response in keratinocytes through its double-stranded RNA binding protein, E3 Journal of Virology. 82: 10735-10746. PMID 18715932 DOI: 10.1128/Jvi.01305-08 |
0.331 |
|
| 2008 |
Freedberg DE, Rigas SH, Russak J, Gai W, Kaplow M, Osman I, Turner F, Randerson-Moor JA, Houghton A, Busam K, Timothy Bishop D, Bastian BC, Newton-Bishop JA, Polsky D. Frequent p16-independent inactivation of p14ARF in human melanoma Journal of the National Cancer Institute. 100: 784-795. PMID 18505964 DOI: 10.1093/Jnci/Djn157 |
0.321 |
|
| 2008 |
Engelhorn ME, Guevara-Patiño JA, Merghoub T, Liu C, Ferrone CR, Rizzuto GA, Cymerman DH, Posnett DN, Houghton AN, Wolchok JD. Mechanisms of immunization against cancer using chimeric antigens. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 773-81. PMID 18301399 DOI: 10.1038/Mt.2008.8 |
0.776 |
|
| 2008 |
Na I, Lu SX, Goldberg GL, Hirschhorn-Cymerman DD, King CG, Smith OM, Suh D, Rao U, Yim N, Holland AM, Penack O, Jenq RR, Ghosh A, Teisch L, Meykler S, ... ... Houghton A, et al. The T Cell Cytolytic Molecules Fas Ligand and TRAIL, the Trafficking Molecules CCR9, β7 Integrin and PSGL-1, and the Immune Modulating Molecules OX40, CEACAM1, and CTLA4 Are Required for Thymic Graft-Versus-Host Disease Blood. 112: 65-65. DOI: 10.1182/Blood.V112.11.65.65 |
0.453 |
|
| 2007 |
Felicetti P, Mennecozzi M, Barucca A, Montgomery S, Orlandi F, Manova K, Houghton AN, Gregor PD, Concetti A, Venanzi FM. Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag. Cytotherapy. 9: 23-34. PMID 18236207 DOI: 10.1080/14653240601048369 |
0.361 |
|
| 2007 |
Santomasso BD, Roberts WK, Thomas A, Williams T, Blachère NE, Dudley ME, Houghton AN, Posner JB, Darnell RB. A T-cell receptor associated with naturally occurring human tumor immunity. Proceedings of the National Academy of Sciences of the United States of America. 104: 19073-8. PMID 18045792 DOI: 10.1073/Pnas.0704336104 |
0.517 |
|
| 2007 |
Orlandi F, Venanzi FM, Concetti A, Yamauchi H, Tiwari S, Norton L, Wolchok JD, Houghton AN, Gregor PD. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6195-203. PMID 17947487 DOI: 10.1158/1078-0432.Ccr-07-0258 |
0.503 |
|
| 2007 |
Wolchok JD, Yuan J, Houghton AN, Gallardo HF, Rasalan TS, Wang J, Zhang Y, Ranganathan R, Chapman PB, Krown SE, Livingston PO, Heywood M, Riviere I, Panageas KS, Terzulli SL, et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 2044-50. PMID 17726460 DOI: 10.1038/Sj.Mt.6300290 |
0.479 |
|
| 2007 |
Houghton CS, Engelhorn ME, Liu C, Song D, Gregor P, Livingston PO, Orlandi F, Wolchok JD, McCracken J, Houghton AN, Guevara-Patiño JA. Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. Vaccine. 25: 5330-42. PMID 17570567 DOI: 10.1016/J.Vaccine.2007.05.008 |
0.44 |
|
| 2007 |
Gilewski TA, Ragupathi G, Dickler M, Powell S, Bhuta S, Panageas K, Koganty RR, Chin-Eng J, Hudis C, Norton L, Houghton AN, Livingston PO. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2977-85. PMID 17504999 DOI: 10.1158/1078-0432.Ccr-06-2189 |
0.383 |
|
| 2007 |
Slovin S, Gregor P, Wolchok J, Pedraza A, Orlandi F, Jefferson M, Fernandez C, Rudolph J, Houghton A, Scher H. A xenogeneic PSMA DNA vaccine for patients (pts) with non-castrate metastatic (NCMPC) and castrate metastatic prostate cancer (CMPC)—A phase I trial of proof of principle Journal of Clinical Oncology. 25: 3073-3073. DOI: 10.1200/Jco.2007.25.18_Suppl.3073 |
0.32 |
|
| 2007 |
Cohen AD, Diab A, Perales MA, Duan F, Jenq R, Rizzuto G, Hirschorn-Cymmerman D, Merghoub T, Wolchok JD, Houghton AN. Agonist anti-GITR antibody induces CD8 T cell-mediated tumor rejection Journal of Clinical Oncology. 25: 3058-3058. DOI: 10.1200/Jco.2007.25.18_Suppl.3058 |
0.781 |
|
| 2007 |
Cohen AD, Hirschhorn-Cymmerman D, Diab A, Perales MA, Merghoub T, Wolchok JD, Houghton AN. Synergistic Tumor Immunity Induced by Chemotherapy and Agonist Anti-GITR Antibody. Blood. 110: 1788-1788. DOI: 10.1182/Blood.V110.11.1788.1788 |
0.55 |
|
| 2006 |
Yuan J, Gallardo HF, Rasalan T, Ranganathan R, Wang J, Zhang Y, Panageas K, Stan R, Young JW, Houghton AN, Wolchok JD. In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring. Cytotherapy. 8: 498-508. PMID 17050255 DOI: 10.1080/14653240600868262 |
0.453 |
|
| 2006 |
Ferrone CR, Perales MA, Goldberg SM, Somberg CJ, Hirschhorn-Cymerman D, Gregor PD, Turk MJ, Ramirez-Montagut T, Gold JS, Houghton AN, Wolchok JD. Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5511-9. PMID 17000687 DOI: 10.1158/1078-0432.Ccr-06-0979 |
0.777 |
|
| 2006 |
Perales MA, Diab A, Cohen AD, Huggins DW, Guevara-Patiño JA, Hubbard VM, Engelhorn ME, Kochman AA, Eng JM, Mortazavi F, Alpdogan O, Terwey TH, Heller G, Wolchok JD, Houghton AN, et al. DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation. Journal of Immunology (Baltimore, Md. : 1950). 177: 4159-67. PMID 16951381 DOI: 10.4049/Jimmunol.177.6.4159 |
0.488 |
|
| 2006 |
Uchi H, Stan R, Turk MJ, Engelhorn ME, Rizzuto GA, Goldberg SM, Wolchok JD, Houghton AN. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Advances in Immunology. 90: 215-41. PMID 16730265 DOI: 10.1016/S0065-2776(06)90006-6 |
0.765 |
|
| 2006 |
Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, Terwey TH, Kochman AA, Lu S, Miles RC, Sakaguchi S, Houghton AN, van den Brink MR. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. Journal of Immunology (Baltimore, Md. : 1950). 176: 6434-42. PMID 16709800 DOI: 10.4049/Jimmunol.176.11.6434 |
0.815 |
|
| 2006 |
Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, Sakaguchi S, Houghton AN. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Research. 66: 4904-12. PMID 16651447 DOI: 10.1158/0008-5472.Can-05-2813 |
0.786 |
|
| 2006 |
Liao JC, Gregor P, Wolchok JD, Orlandi F, Craft D, Leung C, Houghton AN, Bergman PJ. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immunity. 6: 8. PMID 16626110 |
0.328 |
|
| 2006 |
Guevara-Patiño JA, Engelhorn ME, Turk MJ, Liu C, Duan F, Rizzuto G, Cohen AD, Merghoub T, Wolchok JD, Houghton AN. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. The Journal of Clinical Investigation. 116: 1382-90. PMID 16614758 DOI: 10.1172/Jci25591 |
0.819 |
|
| 2006 |
Yuan J, Latouche JB, Hodges J, Houghton AN, Heller G, Sadelain M, Riviere I, Young JW. Langerhans-type dendritic cells genetically modified to express full-length antigen optimally stimulate CTLs in a CD4-dependent manner. Journal of Immunology (Baltimore, Md. : 1950). 176: 2357-65. PMID 16455993 DOI: 10.4049/Jimmunol.176.4.2357 |
0.457 |
|
| 2006 |
Engelhorn ME, Guevara-Patiño JA, Noffz G, Hooper AT, Lou O, Gold JS, Kappel BJ, Houghton AN. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nature Medicine. 12: 198-206. PMID 16444264 DOI: 10.1038/Nm1363 |
0.479 |
|
| 2006 |
Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. Journal of Immunotherapy (Hagerstown, Md. : 1997). 29: 95-101. PMID 16365605 DOI: 10.1097/01.Cji.0000195295.74104.Ad |
0.345 |
|
| 2006 |
Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, Leung C, Liao J, Riviere I, Sadelain M, Hohenhaus AE, Gregor P, Houghton AN, Perales MA, Wolchok JD. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine. 24: 4582-5. PMID 16188351 DOI: 10.1016/J.Vaccine.2005.08.027 |
0.365 |
|
| 2006 |
Wolchok J, Bergman P, Yuan J, Gallardo H, Riviere I, Sadelain M, Liao J, Rasalan T, Wang J, Houghton A. Xenogeneic immunization with tyrosinase DNA vaccines: results from clinical trials in humans and dogs Melanoma Research. 16: S46. DOI: 10.1097/00008390-200609001-00081 |
0.347 |
|
| 2005 |
Goldberg SM, Bartido SM, Gardner JP, Guevara-Patiñio JA, Montgomery SC, Perales MA, Maughan MF, Dempsey J, Donovan GP, Olson WC, Houghton AN, Wolchok JD. Comparison of two cancer vaccines targeting tyrosinase: Plasmid DNA and recombinant alphavirus replicon particles Clinical Cancer Research. 11: 8114-8121. PMID 16299244 DOI: 10.1158/1078-0432.Ccr-05-1410 |
0.435 |
|
| 2005 |
Posnett DN, Engelhorn ME, Houghton AN. Antiviral T cell responses: phalanx or multipronged attack? The Journal of Experimental Medicine. 201: 1881-4. PMID 15967819 DOI: 10.1084/Jem.20050928 |
0.434 |
|
| 2005 |
Houghton AN, Uchi H, Wolchok JD. The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword. Cancer Cell. 7: 403-5. PMID 15894259 DOI: 10.1016/J.Ccr.2005.04.026 |
0.433 |
|
| 2005 |
Gregor PD, Wolchok JD, Turaga V, Latouche JB, Sadelain M, Bacich D, Heston WDW, Houghton AN, Scher HI. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination International Journal of Cancer. 116: 415-421. PMID 15800947 DOI: 10.1002/Ijc.21014 |
0.486 |
|
| 2005 |
Segal NH, Blachere NE, Shiu HY, Leejee S, Antonescu CR, Lewis JJ, Wolchok JD, Houghton AN. Antigens recognized by autologous antibodies of patients with soft tissue sarcoma. Cancer Immunity. 5: 4. PMID 15745419 |
0.361 |
|
| 2005 |
Segal NH, Blachere NE, Guevara-Patiño JA, Gallardo HF, Shiu HY, Viale A, Antonescu CR, Wolchok JD, Houghton AN. Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. Cancer Immunity. 5: 2. PMID 15683221 |
0.349 |
|
| 2005 |
Palomba ML, Roberts WK, Dao T, Manukian G, Guevara-Patiño JA, Wolchok JD, Scheinberg DA, Houghton AN. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 370-9. PMID 15671568 |
0.42 |
|
| 2005 |
Liao J, Gregor P, Orlandi F, Craft DM, Leung C, Houghton AN, Wolchok JD, Bergman PJ. Xenogeneic Human Tyrosinase DNA Vaccination Induces Specific Immune Response in Dogs with Advanced Malignant Melanoma Veterinary and Comparative Oncology. 3: 48-48. DOI: 10.1111/J.1476-5810.2005.0064Y.X |
0.454 |
|
| 2005 |
Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Novosad CA, Brenn S, Ettinger SN, Endicott MM, Finora K, Craft D, Leung C, Liao J, Riviere I, Hohenhaus AE, Houghton A, et al. Phase I & Ib Trials of Murine Tyrosinase ± Human GM-CSF DNA Vaccination in Dogs with Advanced Malignant Melanoma Veterinary and Comparative Oncology. 3: 35-36. DOI: 10.1111/J.1476-5810.2005.0064G.X |
0.372 |
|
| 2005 |
Yuan J, Gallardo HF, Rasalan T, Ranganathan R, Wang J, Zhang Y, Stan R, Young JW, Houghton AN, Wolchok JD. In Vitro Expansion of Antigen-Specific Cytotoxic T Lymphocytes by HLA-A*0201 Transfected K562 for Monitoring of T-cell Responses Journal of Immunotherapy. 28: 635. DOI: 10.1097/01.Cji.0000191020.52426.Fb |
0.429 |
|
| 2004 |
Turk MJ, Guevara-Patiño JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. The Journal of Experimental Medicine. 200: 771-82. PMID 15381730 DOI: 10.1084/Jem.20041130 |
0.786 |
|
| 2004 |
Houghton AN, Guevara-Patiño JA. Immune recognition of self in immunity against cancer. The Journal of Clinical Investigation. 114: 468-71. PMID 15314682 DOI: 10.1172/Jci22685 |
0.494 |
|
| 2004 |
Muriglan SJ, Ramirez-Montagut T, Alpdogan O, Van Huystee TW, Eng JM, Hubbard VM, Kochman AA, Tjoe KH, Riccardi C, Pandolfi PP, Sakaguchi S, Houghton AN, Van Den Brink MR. GITR activation induces an opposite effect on alloreactive CD4(+) and CD8(+) T cells in graft-versus-host disease. The Journal of Experimental Medicine. 200: 149-57. PMID 15249593 DOI: 10.1084/Jem.20040116 |
0.785 |
|
| 2004 |
Ramirez-Montagut T, Blachere NE, Sviderskaya EV, Bennett DC, Rettig WJ, Garin-Chesa P, Houghton AN. FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor. Oncogene. 23: 5435-46. PMID 15133496 DOI: 10.1038/Sj.Onc.1207730 |
0.796 |
|
| 2004 |
Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patiño JA, Perales MA, Mortazavi F, Bacich D, Heston W, Latouche JB, Sadelain M, Allison JP, Scher HI, Houghton AN. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 22: 1700-8. PMID 15068853 DOI: 10.1016/J.Vaccine.2003.10.048 |
0.55 |
|
| 2004 |
Wesley UV, Tiwari S, Houghton AN. Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. International Journal of Cancer. 109: 855-66. PMID 15027119 DOI: 10.1002/Ijc.20091 |
0.383 |
|
| 2004 |
Houghton AN. LIGHTing the way for tumor immunity. Nature Immunology. 5: 123-4. PMID 14749779 DOI: 10.1038/Ni0204-123 |
0.504 |
|
| 2004 |
Diab A, Hubbard VM, Cohen A, Huggins D, Kochman A, Guevarra JA, Engelhorn M, Wolchok JD, van den Brink M, Houghton AN, Perales M. DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mice Following Sub-Lethal Irradiation and Immune Reconstitution. Blood. 104: 3057-3057. DOI: 10.1182/Blood.V104.11.3057.3057 |
0.56 |
|
| 2004 |
Diab A, Perales M, Cohen A, Hubbard VM, Eng J, Huggins D, Engelhorn M, Guevarra JA, Alpdogan O, Wolchok JD, Kochman A, Houghton AN, Brink Mvd. DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mouse Models of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood. 104: 304-304. DOI: 10.1182/Blood.V104.11.304.304 |
0.541 |
|
| 2003 |
Guevara-Patiño JA, Turk MJ, Wolchok JD, Houghton AN. Immunity to cancer through immune recognition of altered self: studies with melanoma. Advances in Cancer Research. 90: 157-77. PMID 14710950 DOI: 10.1016/S0065-230X(03)90005-4 |
0.521 |
|
| 2003 |
Segal NH, Pavlidis P, Antonescu CR, Maki RG, Noble WS, DeSantis D, Woodruff JM, Lewis JJ, Brennan MF, Houghton AN, Cordon-Cardo C. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. The American Journal of Pathology. 163: 691-700. PMID 12875988 DOI: 10.1016/S0002-9440(10)63696-6 |
0.315 |
|
| 2003 |
Ramirez-Montagut T, Turk MJ, Wolchok JD, Guevara-Patino JA, Houghton AN. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene. 22: 3180-7. PMID 12789294 DOI: 10.1038/Sj.Onc.1206462 |
0.831 |
|
| 2003 |
Gold JS, Ferrone CR, Guevara-Patiño JA, Hawkins WG, Dyall R, Engelhorn ME, Wolchok JD, Lewis JJ, Houghton AN. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. Journal of Immunology (Baltimore, Md. : 1950). 170: 5188-94. PMID 12734366 DOI: 10.4049/Jimmunol.170.10.5188 |
0.487 |
|
| 2003 |
Segal NH, Pavlidis P, Noble WS, Antonescu CR, Viale A, Wesley UV, Busam K, Gallardo H, DeSantis D, Brennan MF, Cordon-Cardo C, Wolchok JD, Houghton AN. Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 1775-81. PMID 12721254 DOI: 10.1200/Jco.2003.10.108 |
0.323 |
|
| 2003 |
Hawkins WG, Trcka J, Segal N, Blachere NE, Gold JS, Moroi Y, Bowne WB, Lewis JJ, Wolchok JD, Houghton AN. The role of lipopolysaccharide in T-cell responses following DNA vaccination. Vaccine. 21: 1548-53. PMID 12615452 DOI: 10.1016/S0264-410X(02)00676-X |
0.395 |
|
| 2002 |
Perales MA, Fantuzzi G, Goldberg SM, Turk MJ, Mortazavi F, Busam K, Houghton AN, Dinarello CA, Wolchok JD. GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines. Cytokines, Cellular & Molecular Therapy. 7: 125-33. PMID 12850812 DOI: 10.1080/13684730310000923 |
0.392 |
|
| 2002 |
Srinivasan R, Houghton AN, Wolchok JD. Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue. Cancer Immunity. 2: 8. PMID 12747753 |
0.384 |
|
| 2002 |
Turk MJ, Wolchok JD, Guevara-Patino JA, Goldberg SM, Houghton AN. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunological Reviews. 188: 122-35. PMID 12445286 DOI: 10.1034/J.1600-065X.2002.18811.X |
0.534 |
|
| 2002 |
Houghton AN, Polsky D. Focus on melanoma. Cancer Cell. 2: 275-8. PMID 12398891 DOI: 10.1016/S1535-6108(02)00161-7 |
0.301 |
|
| 2002 |
Trcka J, Moroi Y, Clynes RA, Goldberg SM, Bergtold A, Perales MA, Ma M, Ferrone CR, Carroll MC, Ravetch JV, Houghton AN. Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. Immunity. 16: 861-8. PMID 12121667 DOI: 10.1016/S1074-7613(02)00327-8 |
0.347 |
|
| 2002 |
Schaed SG, Klimek VM, Panageas KS, Musselli CM, Butterworth L, Hwu WJ, Livingston PO, Williams L, Lewis JJ, Houghton AN, Chapman PB. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 967-72. PMID 12006508 |
0.322 |
|
| 2002 |
Perales MA, Blachere NE, Engelhorn ME, Ferrone CR, Gold JS, Gregor PD, Noffz G, Wolchok JD, Houghton AN. Strategies to overcome immune ignorance and tolerance. Seminars in Cancer Biology. 12: 63-71. PMID 11926414 DOI: 10.1006/Scbi.2001.0397 |
0.503 |
|
| 2002 |
Hawkins WG, Gold JS, Blachere NE, Bowne WB, Hoos A, Lewis JJ, Houghton AN. Xenogeneic DNA immunization in melanoma models for minimal residual disease. The Journal of Surgical Research. 102: 137-43. PMID 11796010 DOI: 10.1006/Jsre.2001.6302 |
0.428 |
|
| 2001 |
Gilewski T, Ragupathi G, Bhuta S, Williams LJ, Musselli C, Zhang XF, Bornmann WG, Spassova M, Bencsath KP, Panageas KS, Chin J, Hudis CA, Norton L, Houghton AN, Livingston PO, et al. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proceedings of the National Academy of Sciences of the United States of America. 98: 3270-5. PMID 11248068 DOI: 10.1073/Pnas.051626298 |
0.379 |
|
| 2001 |
Houghton AN, Gold JS, Blachere NE. Immunity against cancer: lessons learned from melanoma. Current Opinion in Immunology. 13: 134-40. PMID 11228404 DOI: 10.1016/S0952-7915(00)00195-3 |
0.514 |
|
| 2000 |
Hawkins WG, Gold JS, Dyall R, Wolchok JD, Hoos A, Bowne WB, Srinivasan R, Houghton AN, Lewis JJ. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery. 128: 273-80. PMID 10923004 DOI: 10.1067/Msy.2000.107421 |
0.479 |
|
| 2000 |
Lewis JJ, Janetzki S, Schaed S, Panageas KS, Wang S, Williams L, Meyers M, Butterworth L, Livingston PO, Chapman PB, Houghton AN. Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. International Journal of Cancer. 87: 391-8. PMID 10897045 DOI: 10.1002/1097-0215(20000801)87:3<391::Aid-Ijc13>3.0.Co;2-K |
0.48 |
|
| 2000 |
Castellino F, Boucher PE, Eichelberg K, Mayhew M, Rothman JE, Houghton AN, Germain RN. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. The Journal of Experimental Medicine. 191: 1957-64. PMID 10839810 DOI: 10.1084/Jem.191.11.1957 |
0.431 |
|
| 2000 |
Houghton AN, Scheinberg DA. Monoclonal antibody therapies - A 'constant' threat to cancer Nature Medicine. 6: 373-374. PMID 10742135 DOI: 10.1038/74621 |
0.337 |
|
| 2000 |
Moroi Y, Mayhew M, Trcka J, Hoe MH, Takechi Y, Hartl FU, Rothman JE, Houghton AN. Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Proceedings of the National Academy of Sciences of the United States of America. 97: 3485-90. PMID 10725409 DOI: 10.1073/Pnas.97.7.3485 |
0.431 |
|
| 2000 |
Janetzki S, Song P, Gupta V, Lewis JJ, Houghton AN. Insect cells as HLA-restricted antigen-presenting cells for the IFN-gamma elispot assay. Journal of Immunological Methods. 234: 1-12. PMID 10669764 DOI: 10.1016/S0022-1759(99)00203-3 |
0.477 |
|
| 2000 |
Schnell S, Young JW, Houghton AN, Sadelain M. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells. Journal of Immunology (Baltimore, Md. : 1950). 164: 1243-50. PMID 10640737 DOI: 10.4049/Jimmunol.164.3.1243 |
0.484 |
|
| 2000 |
Bowne WB, Srinivasan R, Wolchok JD, Hawkins WG, Blachere NE, Dyall R, Lewis JJ, Houghton AN. Coupling and uncoupling of tumor immunity and autoimmunity. The Journal of Experimental Medicine. 190: 1717-22. PMID 10587362 DOI: 10.1084/Jem.190.11.1717 |
0.572 |
|
| 2000 |
Hawkins WG, Gold JS, Houghton AN, Lewis JJ. Xenogeneic DNA vaccination prevents metastasis in a melanoma model of minimal residual disease Journal of the American College of Surgeons. 191. DOI: 10.1016/S1072-7515(00)00426-9 |
0.306 |
|
| 2000 |
Gold JS, Hawkins WG, Dyall R, Blachere NE, Houghton AN, Lewis JJ. B cell deficient mice reject B16 melanoma via T cell mediated immunity that is not associated with autoimmunity Journal of the American College of Surgeons. 191. DOI: 10.1016/S1072-7515(00)00422-1 |
0.444 |
|
| 1999 |
Wesley UV, Albino AP, Tiwari S, Houghton AN. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. The Journal of Experimental Medicine. 190: 311-22. PMID 10430620 DOI: 10.1084/Jem.190.3.311 |
0.374 |
|
| 1999 |
Srinivasan R, Wolchok JD, Bowne WB, Blachere NE, Hawkins WG, Dyall R, Lewis JJ, Houghton AN. XENOGENEIC DNA IMMUNIZATION WITH TYROSINASE RELATED PROTEIN-2 BREAKS TOLERANCE Journla of Immunotherapy. 22: 468. DOI: 10.1097/00002371-199909000-00065 |
0.347 |
|
| 1998 |
Hirschowitz E, Leonard S, Song W, Ferris B, Leopold P, Lewis J, Bowne W, Wang S, Houghton A, Crystal R. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma Gene Therapy. 5: 975-983. PMID 9813669 DOI: 10.1038/Sj.Gt.3300668 |
0.399 |
|
| 1998 |
Dyall R, Bowne WB, Weber LW, LeMaoult J, Szabo P, Moroi Y, Piskun G, Lewis JJ, Houghton AN, Nikolić-Zugić J. Heteroclitic immunization induces tumor immunity. The Journal of Experimental Medicine. 188: 1553-61. PMID 9802967 DOI: 10.1084/Jem.188.9.1553 |
0.502 |
|
| 1998 |
Wolchok JD, Livingston PO, Houghton AN. Vaccines And Other Adjuvant Therapies For Melanoma Hematology-Oncology Clinics of North America. 12: 835-848. PMID 9759582 DOI: 10.1016/S0889-8588(05)70026-5 |
0.319 |
|
| 1998 |
Weber LW, Bowne WB, Wolchok JD, Srinivasan R, Qin J, Moroi Y, Clynes R, Song P, Lewis JJ, Houghton AN. Tumor immunity and autoimmunity induced by immunization with homologous DNA. The Journal of Clinical Investigation. 102: 1258-64. PMID 9739060 DOI: 10.1172/Jci4004 |
0.565 |
|
| 1998 |
Houghton AN, Lloyd KO. Stuck in the MUC on the long and winding road. Nature Medicine. 4: 270-1. PMID 9500594 DOI: 10.1038/Nm0398-270 |
0.438 |
|
| 1998 |
Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma Proceedings of the National Academy of Sciences of the United States of America. 95: 652-656. PMID 9435247 DOI: 10.1073/Pnas.95.2.652 |
0.516 |
|
| 1997 |
Naftzger C, Takechi Y, Kohda H, Hara I, Vijayasaradhi S, Houghton AN. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proceedings of the National Academy of Sciences of the United States of America. 93: 14809-14. PMID 8962137 DOI: 10.1073/Pnas.93.25.14809 |
0.531 |
|
| 1997 |
Lewis JJ, Houghton AN. Definition of tumor antigens suitable for vaccine construction. Seminars in Cancer Biology. 6: 321-7. PMID 8938270 DOI: 10.1016/1044-579X(95)90001-2 |
0.49 |
|
| 1997 |
Nasi ML, Meyers M, Livingston PO, Houghton AN, Chapman PB. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside Melanoma Research. 7: S163. DOI: 10.1097/00008390-199708001-00024 |
0.33 |
|
| 1996 |
Boussiotis VA, Pardo NA, Collins H, Houghton A, Ritz J, Nadler LM, Soiffer RJ. R24 anti-GD3 ganglioside antibody can induce costimulation and prevent the induction of alloantigen-specific T cell clonal anergy. European Journal of Immunology. 26: 2149-54. PMID 8814260 DOI: 10.1002/Eji.1830260928 |
0.383 |
|
| 1995 |
Spielholz C, Heaney ML, Morrison ME, Houghton AN, Vera JC, Golde DW. Granulocyte-macrophage colony-stimulating factor signals for increased glucose uptake in human melanoma cells Blood. 85: 973-980. PMID 7849318 DOI: 10.1182/Blood.V85.4.973.Bloodjournal854973 |
0.333 |
|
| 1995 |
Vijayasaradhi S, Houghton AN. Melanoma and melanocytes: pigmentation, tumor progression, and the immune response to cancer. Advances in Pharmacology (San Diego, Calif.). 32: 343-74. PMID 7748799 DOI: 10.1016/S1054-3589(08)61017-0 |
0.445 |
|
| 1995 |
Hara I, Nguyen H, Takechi Y, Gansbacher B, Chapman PB, Houghton AN. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. International Journal of Cancer. 61: 253-60. PMID 7705956 DOI: 10.1002/Ijc.2910610219 |
0.502 |
|
| 1995 |
Vijayasaradhi S, Doskoch PM, Wolchok J, Houghton AN. Melanocyte differentiation marker gp75, the brown locus protein, can be regulated independently of tyrosinase and pigmentation. The Journal of Investigative Dermatology. 105: 113-9. PMID 7615964 DOI: 10.1111/1523-1747.Ep12313414 |
0.318 |
|
| 1995 |
Hara I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. The Journal of Experimental Medicine. 182: 1609-14. PMID 7595233 DOI: 10.1084/Jem.182.5.1609 |
0.553 |
|
| 1994 |
Casper ES, Cordon-Cardo C, Houghton AN, Steffens TA, McCormack P, Magill GB, Hajdu SI, Brennan MF. Biological study of r24 mouse monoclonal antibody in patients undergoing thoracotomy for pulmonary metastases from soft tissue sarcoma Cancer Investigation. 12: 20-25. PMID 8281462 DOI: 10.3109/07357909409021389 |
0.414 |
|
| 1994 |
Chapman PB, Houghton AN. Non-antibody immunotherapy of cancer. Current Opinion in Immunology. 5: 726-31. PMID 8240734 DOI: 10.1016/0952-7915(93)90128-F |
0.514 |
|
| 1994 |
Houghton AN. Cancer antigens: Immune recognition of self and altered self Journal of Experimental Medicine. 180: 1-4. PMID 8006576 DOI: 10.1084/Jem.180.1.1 |
0.358 |
|
| 1994 |
Mathew S, Morrison ME, Murty VV, Houghton AN, Chaganti RS. Assignment of the DPP4 gene encoding adenosine deaminase binding protein (CD26/dipeptidylpeptidase IV) to 2q23. Genomics. 22: 211-2. PMID 7959771 DOI: 10.1006/Geno.1994.1364 |
0.3 |
|
| 1994 |
Bouchard B, Vijayasaradhi S, Houghton AN. Production and characterization of antibodies against human tyrosinase Journal of Investigative Dermatology. 102: 291-295. PMID 7509835 DOI: 10.1111/1523-1747.Ep12371784 |
0.396 |
|
| 1994 |
Minasian L, Szatrowski T, Rosenblum M, Steffens T, Morrison M, Chapman P, Williams L, Nathan C, Houghton A. Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma Blood. 83: 56-64. DOI: 10.1182/Blood.V83.1.56.56 |
0.386 |
|
| 1993 |
Wang Z, Cao Y, Albino AP, Zeff RA, Houghton A, Ferrone S. Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. The Journal of Clinical Investigation. 91: 684-92. PMID 8432869 DOI: 10.1172/Jci116249 |
0.346 |
|
| 1993 |
Morrison ME, Vijayasaradhi S, Engelstein D, Albino AP, Houghton AN. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. The Journal of Experimental Medicine. 177: 1135-43. PMID 8096237 DOI: 10.1084/Jem.177.4.1135 |
0.382 |
|
| 1993 |
Wang Z, Albino AP, Houghton A, Ferrone S. Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in β2 μmRNA Melanoma Research. 3: 12. DOI: 10.1097/00008390-199303000-00034 |
0.362 |
|
| 1992 |
Steffens TA, Bajorin DF, Houghton AN. Immunotherapy with monoclonal antibodies in metastatic melanoma. World Journal of Surgery. 16: 261-9. PMID 1561808 DOI: 10.1007/Bf02071530 |
0.477 |
|
| 1992 |
Gansbacher PIB, Motzer CIR, Houghton A, Bander N, Minasian OIL, Gastl G, Rosenthal F, Gilboa E, Scheinfeld J, Yang SY, Wong G, Golde D, Reuter V, Livingston P, Bosl G, et al. A Pilot Study of Immunization with Interleukin-2 Secreting Allogeneic HLA-A2 Matched Renal Cell Carcinoma Cells in Patients with Advanced Renal Cell Carcinoma Human Gene Therapy. 3: 691-703. PMID 1482709 DOI: 10.1089/Hum.1992.3.6-691 |
0.322 |
|
| 1992 |
Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlock DR, Titus-Ernstoff L, Bouchard B, Vijayasaradhi S, Houghton AN, Lahti J. Homozygous deletions within human chromosome band 9p21 in melanoma. Proceedings of the National Academy of Sciences of the United States of America. 89: 10557-61. PMID 1438246 DOI: 10.1073/Pnas.89.21.10557 |
0.309 |
|
| 1992 |
Gansbacher B, Zier K, Cronin K, Hantzopoulos P, Bouchard B, Houghton A, Gilboa E, Golde D. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells. Blood. 80: 2817-2825. DOI: 10.1182/Blood.V80.11.2817.2817 |
0.4 |
|
| 1991 |
Wang ZG, Cao Y, D'Urso C, Houghton AN, Ferrone S. Molecular abnormalities in the expression of HLA class-I antigens by melanoma cells. International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement. 6: 101-5. PMID 2066175 DOI: 10.1002/Ijc.2910470720 |
0.401 |
|
| 1991 |
Naftzger C, Houghton AN. Tumor immunology. Current Opinion in Oncology. 3: 93-9. PMID 2043699 DOI: 10.1097/00001622-199102000-00013 |
0.45 |
|
| 1991 |
Lynch SA, Bouchard BN, Vijayasaradhi S, Yuasa H, Houghton AN. Antigens of melanocytes and melanoma. Cancer Metastasis Reviews. 10: 141-50. PMID 1873854 DOI: 10.1007/Bf00049411 |
0.435 |
|
| 1991 |
Vijayasaradhi S, Houghton AN. Purification of an autoantigenic 75-kDa human melanosomal glycoprotein. International Journal of Cancer. 47: 298-303. PMID 1671031 DOI: 10.1002/Ijc.2910470221 |
0.345 |
|
| 1990 |
Urmacher C, Cordon-Cardo C, Houghton AN. Tissue distribution of GD3 ganglioside detected by mouse monoclonal antibody R24. The American Journal of Dermatopathology. 11: 577-81. PMID 2604027 DOI: 10.1097/00000372-198912000-00013 |
0.354 |
|
| 1990 |
Vijayasaradhi S, Bouchard B, Houghton AN. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product Journal of Experimental Medicine. 171: 1375-1380. PMID 2324688 DOI: 10.1084/Jem.171.4.1375 |
0.315 |
|
| 1990 |
Yuasa H, Scheinberg DA, Houghton AN. Gangliosides of T lymphocytes: Evidence for a role in T-cell activation Tissue Antigens. 36: 47-56. PMID 2270542 DOI: 10.1111/J.1399-0039.1990.Tb01799.X |
0.379 |
|
| 1989 |
Bouchard B, Fuller BB, Vijayasaradhi S, Houghton AN. Induction of pigmentation in mouse fibroblasts by expression of human tyrosine cDNA Journal of Experimental Medicine. 169: 2029-2042. PMID 2499655 DOI: 10.1084/Jem.169.6.2029 |
0.38 |
|
| 1988 |
Thomson TM, Real FX, Murakami S, Cordon-Cardo C, Old LJ, Houghton AN. Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. The Journal of Investigative Dermatology. 90: 459-66. PMID 3280698 DOI: 10.1111/1523-1747.Ep12460906 |
0.476 |
|
| 1988 |
Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Oettgen HF, Old LJ, Houghton AN. Phase I trial of a mouse monoclonal antibody against G(D3) ganglioside in patients with melanoma: Induction of inflammatory responses at tumor sites Journal of Clinical Oncology. 6: 1636-1648. PMID 3171629 DOI: 10.1200/Jco.1988.6.10.1636 |
0.381 |
|
| 1988 |
Houghton AN, Albino AP, Cordon-Cardo C, Davis LJ, Eisinger M. Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation. The Journal of Experimental Medicine. 167: 197-212. PMID 2891780 DOI: 10.1084/Jem.167.1.197 |
0.394 |
|
| 1987 |
Houghton AN, Real FX, Davis LJ, Cordon-Cardo C, Old LJ. Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. The Journal of Experimental Medicine. 165: 812-29. PMID 3102678 DOI: 10.1084/Jem.165.3.812 |
0.392 |
|
| 1986 |
Cote RJ, Morrissey DM, Houghton AN, Thomson TM, Daly ME, Oettgen HF, Old LJ. Specificity analysis of human monoclonal antibodies reactive with cell surface and intracellular antigens. Proceedings of the National Academy of Sciences of the United States of America. 83: 2959-63. PMID 3458255 DOI: 10.1073/Pnas.83.9.2959 |
0.458 |
|
| 1986 |
Albino AP, Houghton AN, Eisinger M, Lee JS, Kantor RR, Oliff AI, Old LJ. Class II histocompatibility antigen expression in human melanocytes transformed by Harvey murine sarcoma virus (Ha-MSV) and Kirsten MSV retroviruses. The Journal of Experimental Medicine. 164: 1710-22. PMID 2430046 DOI: 10.1084/Jem.164.5.1710 |
0.338 |
|
| 1986 |
Real FX, Mattes MJ, Houghton AN, Livingston PO, Lloyd K, Oettgen H. Melanoma tumor antigen and autologous antibody International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology. 13: iii. DOI: 10.1016/0883-2897(86)90154-6 |
0.405 |
|
| 1985 |
Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ. Mouse monoclonal IgG3 antibody detecting G(D3) ganglioside: A phase I trial in patients with malignant melanoma Proceedings of the National Academy of Sciences of the United States of America. 82: 1242-1246. PMID 3883355 DOI: 10.1073/Pnas.82.4.1242 |
0.405 |
|
| 1985 |
Dracopoli NC, Houghton AN, Old LJ. Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity. Proceedings of the National Academy of Sciences of the United States of America. 82: 1470-4. PMID 2983346 DOI: 10.1073/Pnas.82.5.1470 |
0.35 |
|
| 1985 |
Livingston PO, Albino AP, Chung TJ, Real FX, Houghton AN, Oettgen HF, Old LJ. Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer. 55: 713-20. PMID 2981601 DOI: 10.1002/1097-0142(19850215)55:4<713::Aid-Cncr2820550407>3.0.Co;2-D |
0.463 |
|
| 1985 |
Jaeckle KA, Graus F, Houghton A, Cardon-Cardo C, Nielsen SL, Posner JB. Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen. Annals of Neurology. 18: 592-600. PMID 2416270 DOI: 10.1002/Ana.410180513 |
0.361 |
|
| 1984 |
Real FX, Mattes MJ, Houghton AN, Oettgen HF, Lloyd KO, Old LJ. Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody. The Journal of Experimental Medicine. 160: 1219-33. PMID 6237165 DOI: 10.1084/Jem.160.4.1219 |
0.479 |
|
| 1984 |
Dracopoli NC, Rettig WJ, Goetzger TA, Houghton AN, Spengler BA, Oettgen HF, Biedler JL, Old LJ. Three human cell surface antigen systems determined by genes on chromosome 12. Somatic Cell and Molecular Genetics. 10: 475-81. PMID 6206575 DOI: 10.1007/Bf01534852 |
0.389 |
|
| 1984 |
Houghton AN, Thomson TM, Gross D, Oettgen HF, Old LJ. Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon. The Journal of Experimental Medicine. 160: 255-69. PMID 6204001 DOI: 10.1084/Jem.160.1.255 |
0.427 |
|
| 1983 |
Houghton AN, Eisinger M, Albino AP, Cairncross JG, Old LJ. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. The Journal of Experimental Medicine. 156: 1755-66. PMID 7175440 DOI: 10.1084/Jem.156.6.1755 |
0.393 |
|
| 1983 |
Livingston PO, Watanabe T, Shiku H, Houghton AN, Albino A, Takahashi T, Resnick LA, Michitsch R, Pinsky CM, Oettgen HF, Old LJ. Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells. International Journal of Cancer. 30: 413-22. PMID 7141736 DOI: 10.1002/Ijc.2910300406 |
0.462 |
|
| 1983 |
Houghton AN, Brooks H, Cote RJ, Taormina MC, Oettgen HF, Old LJ. Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma. The Journal of Experimental Medicine. 158: 53-65. PMID 6864164 DOI: 10.1084/Jem.158.1.53 |
0.438 |
|
| 1983 |
Livingston PO, Takeyama H, Pollack MS, Houghton AN, Albino A, Pinsky CM, Oettgen HF, Old LJ. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells. International Journal of Cancer. 31: 567-75. PMID 6852975 DOI: 10.1002/Ijc.2910310507 |
0.475 |
|
| 1983 |
Cote RJ, Morrissey DM, Houghton AN, Beattie EJ, Oettgen HF, Old LJ. Generation of human monoclonal antibodies reactive with cellular antigens. Proceedings of the National Academy of Sciences of the United States of America. 80: 2026-30. PMID 6572959 DOI: 10.1073/Pnas.80.7.2026 |
0.431 |
|
| 1983 |
Marko O, Houghton AN, Eisinger M. Purification of human melanocytes by monoclonal antibody combined with Percoll gradients. Experimental Cell Research. 142: 309-15. PMID 6293851 DOI: 10.1016/0014-4827(82)90372-X |
0.368 |
|
| 1982 |
Albino AP, Lloyd KO, Houghton AN, Oettgen HF, Old LJ. Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. The Journal of Experimental Medicine. 154: 1764-78. PMID 6976407 DOI: 10.1084/Jem.154.6.1764 |
0.473 |
|
| 1982 |
Cairncross JG, Mattes MJ, Beresford HR, Albino AP, Houghton AN, Lloyd KO, Old LJ. Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets. Proceedings of the National Academy of Sciences of the United States of America. 79: 5641-5. PMID 6182568 DOI: 10.1073/Pnas.79.18.5641 |
0.419 |
|
| 1981 |
Houghton AN, Taormina MC, Ikeda H, Watanabe T, Oettgen HF, Old LJ. Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Proceedings of the National Academy of Sciences of the United States of America. 77: 4260-4. PMID 6933476 DOI: 10.1073/Pnas.77.7.4260 |
0.411 |
|
| Show low-probability matches. |